Loading
How many different kinds of bacteria live in the gut and which ones dominate. Higher diversity and certain species are linked with better immunotherapy response; antibiotics and poor diet reduce both.
Alpha diversity (within a person) and specific taxa (Faecalibacterium, Ruminococcaceae, Akkermansia muciniphila, Bifidobacterium) associate with checkpoint-inhibitor response, though the taxa differ between cohorts and countries, and no microbiome test is validated for clinical use. Diet (fibre), antibiotics, proton-pump inhibitors and probiotics are the main modifiable determinants. Causality is supported by mouse FMT experiments and by early human FMT trials.
Showing the technology this term belongs to: Dietary fibre and the gut microbiome for immunotherapy response.
Shares MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma, FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh), Faecal microbiota transplantation for PD-1 non-responders, No one can predict who responds to immunotherapy.
Shares FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh), Faecal microbiota transplantation for PD-1 non-responders, Microbiome-tumour interactions.
Shares Hallmark (2022): polymorphic microbiomes, FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh), Faecal microbiota transplantation for PD-1 non-responders, Microbiome-tumour interactions.
Shares Geographic and age variations in mutational processes in colorectal cancer, Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation.
Shares Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Probiotics, antibiotics and stewardship around immunotherapy, No one can predict who responds to immunotherapy.
Shares Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Dietary fibre and the gut microbiome for immunotherapy response, No one can predict who responds to immunotherapy.
Shares Geographic and age variations in mutational processes in colorectal cancer, Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation.
Shares Geographic and age variations in mutational processes in colorectal cancer, Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation.